News

Should You Buy Gilead Stock At $110?
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
Stocktwits on MSN15h
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention
Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...
The Independent5h
UNAIDS urges Gilead to drop price of new HIV prevention drug
The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The ...
Fierce Pharma1d
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
The BMJ4h
“Hard to justify” $28 000 price tag for breakthrough HIV prevention treatment, says UN agency
A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...
Zacks Investment Research on MSN1d
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Pharmabiz12h
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...
CSRWire1d
Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award
Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...